Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Clinical trial NCT05635734 · COMPLETED
Trial details
- NCT number
- NCT05635734
- Sponsor
- Cantex Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-05
- Primary completion
- 2026-04-30
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.